NeuroSense Therapeutics Announces 1-For-20 Reverse Stock Split, Effective Sept. 14

Benzinga Newsdesk www.benzinga.com Neutral 93.3%

Neg 0% Neu 93.3% Pos 0%

SEC. https://www.sec.gov/Archives/edgar/data/1875091/000121390026098414/ea0304823-6k_neurosense.htm

Comments

No comments yet. Be the first!